Spots Global Cancer Trial Database for ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
Official Title: ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Study ID: NCT00959959
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
UCLA, Los Angeles, California, United States
San Bernardino Urological Associates, San Bernardino, California, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada & US Oncology Research, Las Vegas, Nevada, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Greenville Hospital System University Medical Center, Greenville, South Carolina, United States
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Contact Details
Name: R. B. Montgomery, MD
Affiliation: University of Washington
Role: PRINCIPAL_INVESTIGATOR
Name: M. E. Taplin, MD
Affiliation: Dana-Farber Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
